Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
T Asselah,
Christophe HEZODE,
RB Qaqish,
M ElKhashab,
T Hassanein,
G Papatheodoridis,
JJ Feld,
C Moreno,
S Zeuzem,
P Ferenci,
Y Yu,
R Redman,
T Pilot-Matias,
N Mobashery,
Lencet Gastroenterol Hepatol. 01/09/2016;1(1) : 25-35 10.1016/S2468-1253(16)30001-2. 16/06/2016
A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.
GR Foster,
K Chayama,
WL Chuang,
H Fainboim,
M Farkkila,
A Gadano,
GB Gaeta,
Christophe HEZODE,
Y Inada,
J Heo,
H Kumada,
SN Lu,
P Marcellin,
C Moreno,
SK Roberts,
SI Strasser,
AJ Thompson,
J Toyota,
SW Paik,
JM Vierling,
AL Zignego,
D Cohen,
F McPhee,
M Wind-Rotolo,
S Srinivasan,
M Hruska,
H Myler,
SD Portsmouth,
Springerplus. 19/08/2016;5(1) : 1365 10.1186/s40064-016-2920-z.
Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension.
L Savale,
MC Chaumais,
D Montani,
X Jais,
Christophe HEZODE,
TM Antonini,
A Coilly,
JC Duclos-Vallee,
D Samuel,
G Simonneau,
M Humbert,
O Sitbon,
Chest. 01/07/2016;150(1) : 256-258 10.1016/j.chest.2016.04.031.
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
ZM Younossi,
M Stepanova,
J Feld,
S Zeuzem,
I Jacobson,
K Agarwal,
Christophe HEZODE,
F Nader,
L Henry,
S Hunt,
J Hepatol. 01/07/2016;65(1) : 33-39 10.1016/j.jhep.2016.02.042 05/03/2016
Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
Christophe HEZODE,
Stephane CHEVALIEZ,
G Scoazec,
Alexandre SOULIER,
A Varaut,
Magali BOUVIER-ALIAS,
Isaac RUIZ,
F Roudot-Thoraval,
A Mallat,
Cyrille FERAY,
Jean-Michel PAWLOTSKY,
Hepatology 01/06/2016;63(6) : 1809-1816 10.1002/hep.28491 10/03/2016
Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).
V Leroy,
P Angus,
JP Bronowicki,
GJ Dore,
Christophe HEZODE,
S Pianko,
S Pol,
K Stuart,
E Tse,
F McPhee,
R Bhore,
MJ Jimenez-Exposito,
AJ Thompson,
Hepatology. 01/05/2016;63(5) : 1430-1441 10.1002/hep.28473. 04/05/2016
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.
S Zeuzem,
Christophe HEZODE,
JP Bronowicki,
V Loustaud-Ratti,
F Gea,
M Buti,
A Olveira,
T Banyai,
MT Al-Assi,
J Petersen,
D Thabut,
A Gadano,
R Pruitt,
M Makara,
M Bourliere,
S Pol,
M Beumont-Mauviel,
S Ouwerkerk-Mahadevan,
G Picchio,
M Bifano,
F McPhee,
N Boparai,
K Cheung,
EA Hughes,
S Noviello,
J Hepatol. 01/02/2016;64(2) : 292-300 10.1016/j.jhep.2015.09.024. 08/10/2015